0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Minimal Residual Disease as a Potential Surrogate End Point—Lingering Questions
Nicole J. Gormley, MD; Ann T. Farrell, MD; Richard Pazdur, MD
JAMA Oncology
Original Investigation  | 
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma A Meta-analysis
Nikhil C. Munshi, MD; Herve Avet-Loiseau, PhD; Andy C. Rawstron, PhD; et al.
JAMA Oncology
Editorial  | 
Adjuvant Therapy for Colon Cancer Small Steps Toward Precision Medicine
Axel Grothey, MD; Daniel J. Sargent, PhD
JAMA Oncology
Original Investigation  | 
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial
Nan Song, PhD; Katherine L. Pogue-Geile, PhD; Patrick G. Gavin, BS; et al.